📊 NEUP Key Takeaways
Is Neuphoria Therapeutics Inc. (NEUP) a Good Investment?
Neuphoria Therapeutics is a pre-revenue pharmaceutical company burning cash at an unsustainable rate (-$10.2M operating cash outflow) with negative margins across all profitability metrics (-62.1% operating margin, -51.4% net margin). While the balance sheet provides 2-3 years of runway and EPS improved 98.8% YoY, the company must demonstrate significant revenue acceleration and pathway to profitability to justify continued losses.
Neuphoria shows strong liquidity and zero leverage, providing roughly two years of runway to fund operations while revenue has begun to materialize. However, profitability remains deeply negative with sizable operating and free cash outflows, and revenue growth visibility is unclear. Maintain a neutral stance pending evidence of sustained top-line growth and margin improvement.
Why Buy Neuphoria Therapeutics Inc. Stock? NEUP Key Strengths
- Fortress balance sheet with $22.2M cash, 0.0x debt/equity ratio, and minimal liabilities ($6.9M)
- Exceptional liquidity position with 9.04x current ratio provides substantial financial flexibility
- EPS improvement trend (+98.8% YoY) indicates operational losses are narrowing
- Robust cash position and 9.0x current ratio
- No long-term debt and low liabilities
- EPS improved materially YoY despite losses
NEUP Stock Risks: Neuphoria Therapeutics Inc. Investment Risks
- Severe cash burn (-$10.2M free cash flow) with only 2-3 years of runway at current burn rate despite strong cash reserves
- Deeply unprofitable operations with -$9.7M operating income on $15.6M revenue (-62.1% operating margin)
- Pre-commercial stage biotech with execution risk: no visible revenue growth trajectory, limited pipeline visibility, and high probability of dilutive capital raises needed
- Sustained negative free cash flow and cash burn
- Unclear revenue trajectory and gross margin visibility
- Potential need for future equity financing if burn persists
Key Metrics to Watch
- Operating cash flow trend and cash runway longevity relative to clinical trial progression
- Revenue growth acceleration and gross margins as products approach/enter commercialization
- Path to operating profitability and timeline to break-even or next major clinical milestone
- Operating cash flow (burn) and cash runway
- Revenue growth YoY and operating margin trend
Neuphoria Therapeutics Inc. (NEUP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.04x current ratio provides a solid financial cushion.
NEUP Profit Margin, ROE & Profitability Analysis
NEUP vs Healthcare Sector: How Neuphoria Therapeutics Inc. Compares
How Neuphoria Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neuphoria Therapeutics Inc. Stock Overvalued? NEUP Valuation Analysis 2026
Based on fundamental analysis, Neuphoria Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neuphoria Therapeutics Inc. Balance Sheet: NEUP Debt, Cash & Liquidity
NEUP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neuphoria Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-18.62 indicates the company is currently unprofitable.
NEUP Revenue Growth, EPS Growth & YoY Performance
NEUP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $15.0M | -$804.8K | $-2.83 |
| Q2 2025 | $662.7K | -$804.8K | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Neuphoria Therapeutics Inc. Dividends, Buybacks & Capital Allocation
NEUP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neuphoria Therapeutics Inc. (CIK: 0001191070)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NEUP
What is the AI rating for NEUP?
Neuphoria Therapeutics Inc. (NEUP) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NEUP's key strengths?
Claude: Fortress balance sheet with $22.2M cash, 0.0x debt/equity ratio, and minimal liabilities ($6.9M). Exceptional liquidity position with 9.04x current ratio provides substantial financial flexibility. ChatGPT: Robust cash position and 9.0x current ratio. No long-term debt and low liabilities.
What are the risks of investing in NEUP?
Claude: Severe cash burn (-$10.2M free cash flow) with only 2-3 years of runway at current burn rate despite strong cash reserves. Deeply unprofitable operations with -$9.7M operating income on $15.6M revenue (-62.1% operating margin). ChatGPT: Sustained negative free cash flow and cash burn. Unclear revenue trajectory and gross margin visibility.
What is NEUP's revenue and growth?
Neuphoria Therapeutics Inc. reported revenue of $15.6M.
Does NEUP pay dividends?
Neuphoria Therapeutics Inc. does not currently pay dividends.
Where can I find NEUP SEC filings?
Official SEC filings for Neuphoria Therapeutics Inc. (CIK: 0001191070) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NEUP's EPS?
Neuphoria Therapeutics Inc. has a diluted EPS of $-2.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NEUP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Neuphoria Therapeutics Inc. has a SELL rating with 66% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NEUP stock overvalued or undervalued?
Valuation metrics for NEUP: ROE of -27.1% (sector avg: 15%), net margin of -51.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NEUP stock in 2026?
Our dual AI analysis gives Neuphoria Therapeutics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NEUP's free cash flow?
Neuphoria Therapeutics Inc.'s operating cash flow is $-10.2M, with capital expenditures of N/A. FCF margin is -65.4%.
How does NEUP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -51.4% (avg: 12%), ROE -27.1% (avg: 15%), current ratio 9.04 (avg: 2).